Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.

ABSTRACT:

Objectives

Budesonide/formoterol (BF) Spiromax ^® is an inhaled corticosteroid/long-acting β₂-agonist fixed-dose combination (FDC) inhaler, designed to minimise common inhaler errors and provide reliable and consistent dose delivery in asthma and chronic obstructive pulmonary disease (COPD). We evaluated non-inferiority of BF Spiromax after changing from another FDC inhaler, compared with continuing the original inhaler.

Methods

Patients with asthma and/or COPD who switched to BF Spiromax were matched (1:3) with non-switchers. Data were obtained from the Optimum Patient Care Research Database and Clinical Practice Research Datalink in the UK. The primary end point was the proportion of patients achieving disease control (using the risk domain cont

SUBMITTER: Voorham J 

PROVIDER: S-EPMC6224753 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature